Mostrando 10 resultados de: 23
Filtros aplicados
Subtipo de publicación
Article(23)
Publisher
New England Journal of Medicine(5)
The Lancet(3)
Canadian Journal of Cardiology(2)
Circulation(2)
Diabetes Care(2)
Área temáticas
Enfermedades(22)
Farmacología y terapéutica(14)
Fisiología humana(9)
Medicina y salud(9)
Salud y seguridad personal(3)
Basal insulin and cardiovascular and other outcomes in dysglycemia
ArticleAbstract: Background: The provision of sufficient basal insulin to normalize fasting plasma glucose levels mayPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., Díaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusBlood-pressure and cholesterol lowering in persons without cardiovascular disease
ArticleAbstract: BACKGROUND Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase tPalabras claves:Autores:Accini J.L., Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., McKelvie R., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusBlood-pressure lowering in intermediate-risk persons without cardiovascular disease
ArticleAbstract: BACKGROUND Antihypertensive therapy reduces the risk of cardiovascular events among high-risk personPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., McKelvie R., Molina D.I., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Wilkinson J., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusCardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)
ArticleAbstract: OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutralPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., DIaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
ArticleAbstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoBPalabras claves:acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitorsAutores:Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.Fuentes:scopusAlirocumab and cardiovascular outcomes after acute coronary syndrome
ArticleAbstract: BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemicPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Ducrocq G., Eapen Z., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Quintero K., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valdovinos P.C.M., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:scopusDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
ArticleAbstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucaPalabras claves:antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonistAutores:Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:scopusEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopusEffect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: The glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)
ArticleAbstract: OBJECTIVE-To evaluate the effects of insulin glargine and n-3 polyunsaturated fatty acid (n- 3FA) suPalabras claves:Autores:Bosch J.J., DIaz R., Dyal L., Gerstein H.C., Hâncu N., Hanefeld M., Krum H., Lonn E.M., McQueen M.J., PATRICIO LOPEZ -JARAMILLO, Ramachandran A., Rydén L.E., Smith S., Yusuf S.Fuentes:googlescopusDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
ArticleAbstract: Background: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascularPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Riesmeyer J.S., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopus